National Jewish Health, Department of Pediatrics, The University of Colorado Denver School of Medicine, Denver, CO 80206, USA.
Clin Exp Allergy. 2010 Aug;40(8):1163-74. doi: 10.1111/j.1365-2222.2010.03523.x. Epub 2010 Jun 7.
A novel nutritional formula (NNF) enriched in eicosapentaenoic (EPA) and gamma-linolenic fatty acids and antioxidants reduces airway inflammation and improves clinical outcomes in critically ill patients, but NNF has not been evaluated in chronic inflammatory diseases such as persistent asthma.
To evaluate the efficacy, compliance, and safety of NNF in asthmatic children.
Children, 6-14 years of age, with mild to moderate persistent asthma, on as needed albuterol alone, were randomized to receive daily NNF (n=23) or control formula (n=20) for 12 weeks, with multiple assessments of asthma control, spirometry, measures of airway inflammation, formula tolerance, and adverse events.
Daily consumption of either NNF or a control formula showed improvement in asthma-free days over time (P=0.04) but there was no difference between groups. However, the NNF group had lower exhaled nitric oxide levels compared with the control group at weeks 4, 8, and 12 (P<0.05). An overall group difference in log FEV1 PC20 (P=0.05) was found in favour of the NNF group as well. Significantly higher levels of EPA in plasma (P<0.01) and peripheral blood mononuclear cell (PBMC) (P<0.01) phospholipids in the NNF group compared with control group within 2 weeks indicated good adherence with daily NNF intake. There were no differences in adverse events for NNF vs. control after 12 weeks.
Both NNF and control groups demonstrated improvement in asthma-free days. NNF-treated group had reduced biomarkers of disease activity. Rapid PBMC fatty acid composition changes reflected an anti-inflammatory profile. Dietary supplementation with NNF was safe and well tolerated (ClinicalTrials.gov number NCT01087710).
一种富含二十碳五烯酸（EPA）和γ-亚麻酸及抗氧化剂的新型营养配方（NNF）可降低危重症患者的气道炎症并改善临床结局，但尚未在持续性哮喘等慢性炎症性疾病中进行评估。
评估 NNF 在哮喘儿童中的疗效、依从性和安全性。
选择年龄 6-14 岁、按需使用沙丁胺醇治疗的轻至中度持续性哮喘患儿，随机分为每日接受 NNF（n=23）或对照配方（n=20）治疗 12 周，评估哮喘控制情况、肺量计检查、气道炎症指标、配方耐受性和不良事件。
无论是 NNF 组还是对照配方组，每日摄入均显示哮喘无发作天数随时间推移有所改善（P=0.04），但两组之间无差异。然而，与对照组相比，NNF 组在第 4、8 和 12 周时呼气一氧化氮水平较低（P<0.05）。FEV1 PC20 的总体组间差异也有利于 NNF 组（P=0.05）。此外，在 NNF 组中，与对照组相比，血浆和外周血单个核细胞（PBMC）磷脂中的 EPA 水平在 2 周内显著升高（P<0.01），表明每日 NNF 摄入的依从性良好。12 周后，NNF 与对照组相比，不良事件无差异。
NNF 和对照组均显示哮喘无发作天数的改善。NNF 治疗组疾病活动的生物标志物减少。PBMC 脂肪酸组成的快速变化反映了抗炎特征。NNF 膳食补充剂安全且耐受性良好（ClinicalTrials.gov 编号 NCT01087710）。
